C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
about
Clinically Available Medicines Demonstrating Anti-Toxoplasma ActivityFluoropyrimidine ActivityA phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.Central neurotoxicity in cancer chemotherapy: pharmacogenetic insights.Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Pharmacogenetics and pharmacogenomics in rheumatology.Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancerIdentification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancerMethylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Association Study between Folate Pathway Gene Single Nucleotide Polymorphisms and Gastric Cancer in KoreansPharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicityA retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer pMethylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case-control studiesMicroRNAs and pharmacogenomics.5-Fluorouracil pharmacogenomics: still rocking after all these years?A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia.Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Gastric cancer pharmacogenetics: progress or old tripe?Pediatric perspective on pharmacogenomics.New criteria for supplementation of selected micronutrients in the era of nutrigenetics and nutrigenomics.Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy.PharmGKB summary: fluoropyrimidine pathwaysDNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis.Polymorphisms of MTHFR C677T and A1298C association with oral carcinoma risk: a meta-analysis.MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4,421 individuals.Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients.An update on vitamin B12-related gene polymorphisms and B12 status.The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer.Characterization of a Rare Nonpathogenic Methylenetetrahydrofolatereductase (MTHFR) Gene Mutation p.Lys215del in a Southern Italian family.More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate.
P2860
Q26782581-0AB7F2AF-DEAD-48F3-AD4D-06D75A416FE8Q29883401-64D9D1F4-C6A4-4445-BAEF-2BA586447F56Q33424920-6120C747-25A5-467A-AA4B-4884301F1334Q33857581-B533983E-1578-46B0-942A-09622E7B9F0DQ33874148-5602F51B-1BC6-4696-9F74-D432503CD6FDQ34070615-D238937E-6537-41BE-B362-827872099690Q34538305-3E7E7EE2-09BD-4E74-82BA-A0B09602029AQ34737674-726E3A59-3712-4FB3-9C11-14CB948D0883Q34877504-781D31A6-F35B-4689-B5F9-E39FF0FC6585Q35432484-A823D1A2-0331-41F0-B13E-F1E31EC43E09Q35460703-8FD0013C-A4E2-4BAF-BF42-8BBB33211B1CQ35623320-4164C600-7EC7-43C4-9142-EA4B46D0B6E6Q36111221-39FC5FDA-77A2-448A-871B-AD5D3F8D600EQ36117701-AC19F93E-3A7A-4899-9A2D-927CCC369721Q36381865-6A2CCF08-3E53-4A96-A680-5843B471F210Q36959145-350B1F79-CCFB-488B-B27A-4A58C74C5754Q37580616-7610B38E-F77C-476B-9672-524C78FDC339Q37598444-78DD12EB-6202-4A72-9E62-CF600D77A4BAQ37736453-8888701C-3E6B-427E-8CB1-072995A817F5Q37844550-5EF58767-BB55-44BC-BF86-B58A86F7233EQ38054428-8736F708-BD44-4D67-83A8-9C5F293DE69EQ38080147-747FDFD6-02CF-4CBD-A95A-AF8BB45F869DQ38120288-DAEA28FE-1AD8-45FC-B854-EC4791B21E2CQ38162869-DE2D1A35-620D-469A-A5E2-6478799AF0DEQ38195644-86604EEF-0C57-46D7-82E3-B0E43B8F5B6EQ38539917-2FD3CE46-72B9-44E6-985D-E0D3B15508E2Q39043677-F7B3982C-B691-4532-BB3B-94C7FDE33001Q39128356-C16A86E9-2473-4454-9F4D-0ADBA3D3AC3EQ39230513-DAC1DFC5-6F93-4C21-91C7-6D77E62C8D8BQ42178970-57CC6166-C85B-4FD0-B04E-8FEFCF8994DFQ42749109-747E6175-F4CE-4B67-A638-99DADDC094C7Q43053804-B6C78526-6C4A-4117-91E7-C0D330325273Q43716583-D80AAFFB-CF6A-4339-9AEA-C56DFB1F4181Q43737687-A133B7DB-C94A-4E54-9BC2-9980FB5C7BF8Q44865206-80A2782A-0B65-4544-8C6E-07FAC2F3120FQ47985415-6CF13D6A-BFC6-4D70-BBE9-02383E3C9C76Q50256416-0B27F85D-4885-49A1-A235-7EF58D62ECA3Q50856077-F3DEAE46-8DEB-4C73-A4EE-D7E46EA49DCFQ53816604-BE9E1522-B227-42B7-B260-51B32D99C77FQ55167640-80B32772-30E1-417F-B8F6-71983659C61B
P2860
C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@ast
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@en
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@nl
type
label
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@ast
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@en
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@nl
altLabel
C677T and A1298C MTHFR polymor ...... -based therapy personalisation
@en
prefLabel
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@ast
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@en
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@nl
P1476
C677T and A1298C MTHFR polymor ...... based therapy personalisation.
@en
P2093
Elena De Mattia
Giuseppe Toffoli
P304
P356
10.1016/J.EJCA.2008.12.004
P407
P577
2009-05-01T00:00:00Z